Home » FDA Awards Destiny Pharma QIDP Designation for Staph Drug
FDA Awards Destiny Pharma QIDP Designation for Staph Drug
Antimicrobial drugmaker Destiny Pharma has won qualified infectious disease product designation for its lead candidate XF-73 to prevent postsurgical staph infections, including multiple drug-resistant MRSA.
Phase 1/2a studies conducted in Europe show the compound reduces the number of bacteria in the nose quickly. XF-73 (exeporfinium chloride) is being studied in a clinical trial sponsored by NIH’s National Institute of Allergy and Infectious Diseases that is expected to be completed shortly.
Upcoming Events
-
21Oct